38 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public … and security and physician payment and pricing transparency laws.
The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity
424B5
MREO
Mereo Biopharma Group Plc
10 Feb 21
Prospectus supplement for primary offering
4:53pm
shares are admitted to trading on AIM is required pursuant to Chapter 5 of the Disclosure Guidance and Transparency Rules of the U.K. Financial Conduct
424B5
MREO
Mereo Biopharma Group Plc
9 Feb 21
Prospectus supplement for primary offering
5:24pm
in the United Kingdom whose shares are admitted to trading on AIM is required pursuant to Chapter 5 of the Disclosure Guidance and Transparency Rules
6-K
EX-99.1
orik5 ey0095h6
12 Nov 20
Current report (foreign)
6:15am
424B5
w1u7zysf0aicawhn7eoe
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
EX-1.2
ztxrr0j7xp8fcr97ajp4
6 Oct 20
Shelf registration (foreign)
4:25pm
F-3
xjqak7
6 Oct 20
Shelf registration (foreign)
4:25pm
6-K
EX-99.2
2e87tvf
30 Jun 20
Result of Annual General Meeting
4:07pm
6-K
EX-10.1
8d81czpn zdh
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
F-1/A
y976fgt7 jvw
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
1aw 0ular0un9ykwdbx
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-99.1
2papmd
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
F-1
brz6t
18 Feb 20
Registration statement (foreign)
5:15pm
6-K
EX-99.1
3vvdyhwf
10 Feb 20
Current report (foreign)
7:20am
6-K
psir5j
21 Jun 19
Current report (foreign)
11:10am
20-F
EX-4.13.1
tne6jf8 oy6pmtfie1j
29 Apr 19
Annual report (foreign)
4:59pm